ZOSYN 2.25 for Intravenous Injection, ZOSYN 4.5 for Intravenous Injection and ZOSYN 4.5 for I.V. Infusion Bag (Special drug use-results survey of ZOSYN in pediatric patients with febrile neutropenia)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223102

Enrollment

120

Registered

2016-02-10

Start date

2016-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febrile neutropenia

Interventions

investigational material(s) Generic name etc : ZOSYN 2.25 for Intravenous Injection, ZOSYN 4.5 for Intravenous Injection. ZOSYN 4.5 for I.V. Infusion Bag INN of investigational material : tazobactam,

2.25 for Intravenous Injection. ZOSYN

4.5 for Intravenous Injection: The usual pediatric dosage for intravenous infusion is a 90 mg/kg single dose, four times daily. If necessary, ZOSYN may be injected slowly as an intravenous bolus infus

4.5 for I.V. Infusion Bag: The usual pediatric dosage for intravenous infusion is a 90 mg/kg single dose, four times daily. However, the upper limit of the dosage is equal to the one for adults: 4.5 g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Under 15 years-old. 2. The case that have not enrolled in this study. 3. The case that can be given the safety assessment of this agent (The case that has not given this agent to a past).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Safety:Adverce event expression situation Efficacy:Clinical response, Bacteriological effect Side effect frequencies calculation Calculation of the clinical response (response rate) and the bacteriological effect (disappearance rate)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026